2025-09-08 06:23Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the Biopharma industry in North America with a comprehensive analysis of the US drug market as per IQVIA Rx data [1][6]. Core Insights - The Total Prescription Year-over-Year (YoY) growth for the week ending August 29, 2025, was reported at +1.7%, a decrease from +2.3% the previous week and +2.6% over the past 12 weeks [1][2]. - The rolling 4-week TRx YoY change was +2.3%, while the rolling 12-week TRx YoY was +2.6% [2]. - The Extended Unit (EUTRx) weekly YoY growth was +2.0%, indicating stronger performance compared to the overall TRx YoY [2]. Company-Specific Developments - Bristol Myers Squibb (BMY): The drug Cobenfy for schizophrenia was approved on September 26, 2024. The current weekly scripts are approximately 2,210, up from 2,160 the previous week. To meet the 2025 consensus expectations, Cobenfy needs to achieve ~129K TRx at a net price of ~$1,200 [3]. - Vertex Pharmaceuticals (VRTX): The drug Journavx for acute pain was approved on January 30, 2025. Current scripts are around 7,280, with hospital scripts making up about 35% of total scripts. To achieve projected sales of $78 million, approximately 349K total scripts are needed [4]. - Gilead Sciences (GILD): The drug Yeztugo was approved on June 18, 2025. The latest total TRx is approximately 470, up from 390 the previous week. Projections for achieving consensus estimates for the second half of 2025 are discussed, with a focus on gross-to-net pricing adjustments [5]. Market Trends and Comparisons - A comparison of launches between GILD's Yeztugo, Descovy, and Apretude is provided, highlighting the uptake among different patient groups and the anticipated growth trajectory [5][9]. - The GLP-1 franchise from Eli Lilly shows significant growth, with Mounjaro and Zepbound experiencing +66% and +233% YoY growth respectively [20][23]. Additional Insights - The call includes a detailed analysis of key products and their respective YoY performance, with notable declines in some established drugs like Humira (-39%) and growth in others like Skyrizi (+44%) [20]. - The COVID vaccine tracking and biosimilar adoption analysis are also mentioned, indicating ongoing trends in the pharmaceutical landscape [12][28]. Conclusion - The conference call provides a comprehensive overview of the current state of the biopharma industry in North America, highlighting both challenges and opportunities for key players in the market. The data reflects a mixed performance across various drugs, with some experiencing significant growth while others face declines.